Edgewise Therapeutics, Inc. 10-Q

Item 5. Other Information None. Item 6. Exhibits See Exhibit Index. ​ 95 Table of Contents EXHIBIT INDEX ​ ​ Exhibit No. Description ​ ​ 31.1† Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 ​ ​ 31.2† Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 14d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 ​ ​ 32.1* Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 ​ ​ 101.INS† XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document ​ ​ 101.SCH† Inline XBRL Taxonomy Extension Schema Document ​ ​ 101.CAL† Inline XBRL Taxonomy Extension Calculation Linkbase Document ​ ​ 101.DEF† Inline XBRL Taxonomy Extension Definition Linkbase Document ​ ​ 101.LAB† Inline XBRL Taxonomy Extension Label Linkbase Document ​ ​ 101.PRE† Inline XBRL Taxonomy Extension Presentation Linkbase Document ​ ​ 104† Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) ​ ˄ Indicates management contract or compensatory plan. ​ * The certifications attached as Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing. ​ †  Filed herewith. ​ ​ 96 ​ Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized. Date: August 9, 2021 ​ ​ ​ ​ ​ EDGEWISE THERAPEUTICS, INC. ​ ​ ​ ​ By: /s/ Kevin Koch ​ Name: Kevin Koch ​ Title: President, Chief Executive Officer and Director ​ ​ (Principal Executive Officer) ​ ​ ​ ​ By: /s/ R. Michael Carruthers ​ Name: R. Michael Carruthers ​ Title: Chief Financial Officer ​ ​ (Principal Financial and Accounting Officer) ​ ​ ​ ​ 97 ​